L-carnitine
Levocarnitine is an endogenous fatty-acid carrier with approved deficiency indications and modest, inconsistent weight-loss evidence. The approved injection is intravenous and indication-specific.
tier A · weight loss · -1.21 kg pooled mean body-weight difference
verdict
Across 37 randomized trials, supplementation produced a modest average weight change, while one direct oral trial in overweight women was negative. This evidence does not validate gray-market IM or SC injections.
the core tension
L-carnitine has a necessary metabolic role and modest pooled supplementation evidence. The leap from that record to an injectable fat-loss claim fails at both the endpoint and route boundaries.
what it is
L-carnitine, or levocarnitine, is the R form of carnitine. It carries long-chain fatty-acid groups into mitochondria and is not a peptide.
what it does
Its established biochemical role enables long-chain fatty-acid oxidation. Raising blood carnitine does not automatically cause fat loss: acute IV studies measured substrate use, and clinical weight results remained modest or null depending on the study.
origin
Levocarnitine is an endogenous molecule. Prescription products include an FDA-approved IV injection for specific deficiency states, while supplements and gray-market injections are separate formulations and evidence questions.
does it work
For weight loss, the best synthesis found a modest pooled reduction, with no significant pooled change in waist circumference or body-fat percentage. A small randomized oral trial found no advantage over placebo. Neither result proves that IM or SC fat-loss injections work.
key facts
- molecular formula: C7H15NO3
- molecular weight: 161.20 g/mol
- amino acids: n/a (small endogenous molecule, not a peptide)
- half-life: 17.4 h apparent terminal value after the specified IV injection; not transferable to oral, IM, or SC products
- type: R-carnitine; zwitterionic fatty-acid carrier
- CAS: 541-15-1
- 37 randomized trials in the weight meta-analysis
- 2,292 participants in that synthesis
- IV only route on the reviewed injection label
frequently asked questions
Is injectable L-carnitine FDA approved?
A levocarnitine injection is approved for specific carnitine-deficiency indications, and the reviewed label says intravenous use only. This is not an approval for IM or SC fat-loss injections.
Does L-carnitine cause weight loss?
The pooled average is modest, and trial results are inconsistent. A 37-trial synthesis found a small mean weight reduction, while a direct oral trial in overweight women found no benefit over placebo.
Does moving fat into mitochondria prove it burns body fat?
No. The carrier mechanism is established, but acute substrate-oxidation experiments and body-weight outcomes are different endpoints.
What is the half-life?
The current injection label reports an apparent terminal half-life of 17.4 hours after a specified IV administration. That number does not describe an oral supplement or an IM or SC gray-market injection.
What safety issues are visible in the label?
The IV label includes serious hypersensitivity reactions and advises INR monitoring with warfarin. Gray-market injections add unresolved product-quality and route risks that the label does not characterize.
related peptides
- semaglutide: compare with the modest L-carnitine supplementation result
- retatrutide: compare without transferring the IV levocarnitine label or PK
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.